Transcranial magnetic stimulation — TMS — is non-invasive cortical stimulation delivered through a magnetic coil placed against the scalp. The pulsed magnetic field produces focal electrical induction in cortex below, depolarizing neurons and inducing plasticity changes in targeted circuits. For depression, the standard target is the left dorsolateral prefrontal cortex; high-frequency stimulation is excitatory, applied to a region that is hypoactive in depression.
- Class
- Non-invasive brain stimulation
- Mechanism
- Pulsed magnetic field produces focal electrical induction in cortex → depolarizes neurons → local and network effects on plasticity. High-frequency stimulation excitatory; low-frequency inhibitory.
- Typical dose
- Standard course: 36 sessions over 6-9 weeks; daily 5x/week. Modern TBS: 3-minute sessions (intermittent TBS).
- FDA indications
- Treatment-resistant depression (FDA-approved), OCD (FDA-approved), smoking cessation (FDA-approved 2020), migraine. Off-label: anxiety, PTSD, others.
- Key adverse effects
- Headache, scalp discomfort at stimulation site, rare seizure (very low risk in screened patients), no memory effects, no anesthesia required
- Representative agents
- Repetitive TMS (rTMS), deep TMS (dTMS), theta-burst stimulation (TBS — shorter sessions)
In-office procedure, no anesthesia, patient awake and can drive afterward. Distinguishes from ECT in tolerability but with smaller effect size. Theta-burst stimulation (TBS) — newer protocol with much shorter sessions (~3 min vs. ~40 min). Maintenance TMS protocols emerging.
Clinical position: TMS is less effective than ECT overall but substantially better tolerated. No anesthesia, no memory effects, outpatient treatment, patient awake throughout, can drive afterward. For the patient with treatment-resistant depression who hasn't responded to multiple antidepressants and is reluctant to consider ECT, TMS is a reasonable middle option.
TMS produces a focal, non-invasive neuromodulation — magnetic pulses that drive plasticity in a targeted cortical circuit without anesthesia or systemic drug exposure.
Mechanism note: TMS is focal, non-invasive plasticity induction with a cognitive-protective profile — its advantage over ECT when severity permits; accelerated protocols are compressing the once-six-week course into days.
Standard protocol: 30-40 minute sessions, five days a week, for 6-9 weeks. Treatment-resistant depression response rates are roughly 30-40% remission — meaningful but smaller than ECT's 60-80%. The patient who responds typically maintains response with periodic maintenance sessions; relapse without maintenance is common.
Theta-burst stimulation (TBS) is the more recent protocol that dramatically reduces session time. Intermittent TBS — about 3 minutes per session — has comparable efficacy to standard 40-minute protocols in trials. The time savings are substantial: a full course can be delivered in much less clinic time. Many TMS programs have transitioned to TBS as the default.
- Cost
- Course (36 sessions) ~$10,000-15,000 retail. Insurance coverage variable but improving.
- Generic status
- Procedure with several FDA-approved devices.
- Formulary typical
- Medicare covers for TRD. Commercial coverage variable; PA typical with documented failed antidepressants.
- Access friction
- Specialty TMS clinic required. 36 daily sessions over 6-9 weeks (or theta-burst protocols, shorter). Substantial time commitment.
Prescriber tip: For TRD after multiple failed medications, TMS is an alternative to ECT with less burden. Refer to certified TMS programs. Many programs handle PA submission.
FDA approvals: treatment-resistant depression, OCD, smoking cessation. The migraine indication is in some markets. Off-label uses include anxiety, PTSD, and others, with varying evidence.
Side effects: scalp discomfort at the stimulation site, headache, occasional facial twitching during stimulation. Seizure risk is very low in screened patients (excluded for seizure history, certain metal implants, intracranial pathology). No anesthesia, no memory effects, no cognitive impairment.
For TRD when ECT is unwanted or unavailable, TMS is the alternative worth considering.